Keyphrases
Chronic Lymphocytic Leukemia
95%
Ibrutinib
47%
Chronic Lymphocytic Leukemia Cells
19%
Rituximab
18%
Relapsed or Refractory
17%
Phase II Study
16%
Fludarabine
12%
Overall Survival
12%
B-cell Receptor Signaling
11%
Acute Myeloid Leukemia
11%
Cyclophosphamide
11%
Complete Remission
11%
Microenvironment
10%
B Cell Receptor
10%
Progression-free Survival
9%
Newly Diagnosed
8%
Bruton Tyrosine Kinase Inhibitor
8%
C-X-C Chemokine Receptor Type 4 (CXCR4)
8%
Chemoimmunotherapy
8%
Leukemia Patients
7%
Acute Lymphoblastic Leukemia
7%
Chronic Myeloid Leukemia
7%
High Risk
7%
Relapsed or Refractory Acute Myeloid Leukemia
7%
Phase II Trial
7%
Adverse Events
7%
Overall Response Rate
6%
Dasatinib
6%
Older Patients
6%
Nave
6%
Chemotherapy
6%
Complete Response
6%
Decitabine
6%
Del17p
6%
Bone Marrow
5%
Leukemia Cells
5%
B-cell Malignancies
5%
Minimal Residual Disease
5%
Nurse-like Cells
5%
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
100%
Ibrutinib
53%
Leukemia Cell
25%
B Lymphocyte Receptor
20%
B Cell
18%
Overall Survival
13%
Acute Lymphoblastic Leukemia
12%
Progression Free Survival
12%
Diseases
12%
Lymphocytic Lymphoma
12%
Acute Myeloid Leukemia
11%
Bruton Tyrosine Kinase Inhibitor
10%
Rituximab
10%
Minimal Residual Disease
9%
Adverse Event
8%
Stromal Cell
8%
Cancer
8%
Targeted Therapy
8%
Chronic Lymphocytic Leukemia
7%
Chemokine Receptor CXCR4
7%
Malignant Neoplasm
7%
Neoplasm
7%
Venetoclax
7%
Leukemia
6%
Bruton Tyrosine Kinase
6%
Philadelphia 1 Chromosome
5%
Cyclophosphamide
5%
Fludarabine
5%
Chemoimmunotherapy
5%
Dasatinib
5%
Chronic Myelogenous Leukemia
5%
Flow Cytometry
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
91%
Ibrutinib
37%
Rituximab
22%
Remission
16%
Overall Survival
16%
Acute Myeloid Leukemia
13%
Fludarabine
13%
Cyclophosphamide
12%
Acute Lymphoblastic Leukemia
12%
Progression Free Survival
11%
Diseases
11%
Leukemia
11%
Chemotherapy
10%
Lymphocytic Lymphoma
9%
B Lymphocyte Receptor
9%
Bruton Tyrosine Kinase Inhibitor
8%
Chronic Myeloid Leukemia
8%
Minimal Residual Disease
8%
Adverse Event
8%
Venetoclax
7%
Malignant Neoplasm
7%
Dasatinib
7%
Chemokine Receptor CXCR4
6%
Imatinib
6%
Decitabine
6%
Cytarabine
5%
Protein Tyrosine Kinase Inhibitor
5%
Drug Resistance
5%
Neoplasm
5%